J Korean Neurol Assoc.  1989 Jun;7(1):26-34.

Flash ERG changes in Parkinson's disease: With reference to medications and clinical forms

• Kim JM
• Han SH
• Lee KW
• Lee SB
• Myung HJ

Abstract

Authors have studied photopic and scotopic flash EPGs for 19 control subjects and 20 patients with Parkinson's disease before and after various anti-Parkinsonian therapy. The following fingings were observed 1. There was no significant difference in implicit time of photopic and scotopic a and b waves between the control and the Parkinsonian groups(P(t)>0.05). 2 Amplitudes of photopic and scotopic a and b-waves were smaller in Parkinsonian group during the pre-medication therapy than in control group(P(t)<0.05) however those of photopic a-and b- waves and scotopic b-wave were normalized with anti-Parkinsonian therapy(P(t)<0.01). 3 Parkinsonian patients treated with dopa preparations showed the significant increases of amplitde of scotopic b wave(P(t)<0.001) but those treated with anticholinergics, Amantadine or Bromocryptine did not(P(t1>0.05). 4. Compared with that of tremor predominant Parkinsonism the amplitudes of photopic and scotopic a-and b-waves were small in patients with akineto-rigidity(P(t)<0.01). Therefore it is concluded that the dopaminergic changes in retinal cells are responsible for producing b wave as well as a wave. So clinically flash EFGs can. Be used beneficially in treating Parkinsonian patients in view of choosing the anti-Parkinsonian drugs and monitoring the effectiveness of therapy.

MeSH Terms

Amantadine
Bromocriptine
Cholinergic Antagonists
Dihydroxyphenylalanine
Humans
Parkinson Disease*
Parkinsonian Disorders
Retinaldehyde
Tremor
Amantadine
Bromocriptine
Cholinergic Antagonists
Dihydroxyphenylalanine
Retinaldehyde